Biogen Inc.
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3055% above fair value
$247.13−4.28 (-1.70%)
Close on Nov 19, 2026Market cap $36.53BP/E 105.6Yield –
Biogen Non-GAAP Cost of Sales by Quarter
Non-GAAP Cost of Sales (Excl. Acquired Intangible Amortization) ($M)
Biogen Non-GAAP Cost of Sales: $553M in Q3 2026, up 8.3% from a year earlier.
Latest, Q3 2026
553
Period ended Sep 30, 2026
Change on a year earlier
+8.3%
510 in Q3 2025
History
14 quarters
Since Q4 2022
Sources
10
Documents cited below
Where the Q3 2026 figure comes from
Source: Biogen Form 8-K (filed 2026-10-28) ↗
Reported in Form 8-K Table 4 (GAAP to Non-GAAP Reconciliation).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Cost of Sales (Excl. Acquired Intangible Amortization) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 553 | +8.3% | Biogen Form 8-K (filed 2026-10-28) ↗ |
| Q2 2026 | Jun 30, 2026 | 612 | +10.4% | Biogen Form 8-K (filed 2026-07-29) ↗ |
| Q1 2026 | Mar 31, 2026 | 610 | +5.2% | Biogen Form 8-K (filed 2026-04-29) ↗ |
| Q3 2025 | Sep 30, 2025 | 510 | -13.9% | Biogen Form 8-K (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 554 | +10.0% | Biogen Form 8-K (filed 2025-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 580 | +16.0% | Biogen Form 8-K (filed 2025-05-01) ↗ |
| Q3 2024 | Sep 30, 2024 | 593 | -10.2% | Biogen Form 8-K (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 504 | -15.0% | Biogen Form 8-K (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 500 | -24.6% | Biogen Form 8-K (filed 2024-04-24) ↗ |
| Q4 2023 | Dec 31, 2023 | 587 | +2.8% | Biogen Form 8-K (filed 2024-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 660 | – | Biogen Form 8-K (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 593 | – | Biogen Form 8-K (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 663 | – | Biogen Form 8-K (filed 2024-04-24) ↗ |
| Q4 2022 | Dec 31, 2022 | 571 | – | Biogen Form 8-K (filed 2024-02-13) ↗ |
Breakdown
What makes up non-GAAP Cost of Sales
Cite this data
StockData. (2026). Biogen Non-GAAP Cost of Sales ($M), quarterly Q4 2022–Q3 2026 [Data set]. Compiled from Biogen SEC filings and investor materials. https://stockdatahq.com/stocks/biib/kpis/ng-cogs
See every metric in the Biogen KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?